Early vs Delayed Belimumab in Lupus An economic evaluation of early vs delayed use of the Blys inhibitor, belimumab (BEL), in systemic lupus erythematosus (SLE) has shown both cost-effectiveness and clinical utility of early BEL initiation in active lupus patients. https://t.co/7unHZhR6Dd